MX2022002239A - Glicovariantes de igm. - Google Patents

Glicovariantes de igm.

Info

Publication number
MX2022002239A
MX2022002239A MX2022002239A MX2022002239A MX2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A MX 2022002239 A MX2022002239 A MX 2022002239A
Authority
MX
Mexico
Prior art keywords
igm
heavy chain
variant
derived
motif
Prior art date
Application number
MX2022002239A
Other languages
English (en)
Inventor
Bruce Keyt
Ramesh Baliga
Dean Ng
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of MX2022002239A publication Critical patent/MX2022002239A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona una molécula de unión aislada derivada de IgM, por ejemplo, un anticuerpo IgM, un anticuerpo similar a IgM u otra molécula de unión derivada de IgM, que incluye al menos una cadena pesada variante derivada de IgM, donde la al menos una cadena pesada variante derivada de IgM incluye una región constante de cadena pesada variante de IgM asociada a un dominio de unión que se une específicamente a una diana, donde al menos un motivo de glicosilación ligado a la asparagina (N) de la región constante de la cadena pesada variante de IgM está mutado para evitar la glicosilación en dicho motivo, y/o se introduce al menos un motivo de glicosilación ligado a la N en la cadena pesada variante de IgM.
MX2022002239A 2019-08-23 2020-08-21 Glicovariantes de igm. MX2022002239A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (1)

Publication Number Publication Date
MX2022002239A true MX2022002239A (es) 2022-03-22

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002239A MX2022002239A (es) 2019-08-23 2020-08-21 Glicovariantes de igm.

Country Status (11)

Country Link
US (1) US20220306760A1 (es)
EP (1) EP4017533A4 (es)
JP (1) JP2022545682A (es)
KR (1) KR20220050166A (es)
CN (1) CN114269380A (es)
AU (1) AU2020337333A1 (es)
BR (1) BR112022003282A2 (es)
CA (1) CA3149350A1 (es)
IL (1) IL290253A (es)
MX (1) MX2022002239A (es)
WO (1) WO2021041250A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560954B1 (en) 2014-04-03 2021-08-04 IGM Biosciences, Inc. Modified j-chain
EP3247728B1 (en) 2015-01-20 2020-04-15 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
EP3274051A4 (en) 2015-03-25 2018-08-22 IGM Biosciences A/S Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN108463245A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j链的结合分子
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
IL311039A (en) * 2021-09-17 2024-04-01 Adimab Llc Anti-CD3 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20146112B (en) * 2007-03-22 2014-06-25 Ucb Pharma Sa Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
US20120316071A1 (en) * 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
CN108463245A (zh) * 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j链的结合分子
AU2016370821A1 (en) * 2015-12-18 2018-07-12 Biogen Ma Inc. Bispecific antibody platform
EP3571222A4 (en) * 2017-01-19 2021-06-16 Cedars-Sinai Medical Center HIGHLY MULTIPLEXED MASS SPECTROMETRY-BASED PROCESSES ALLOWING THE MEASUREMENT OF 72 HUMAN PROTEINS
CN110612124B (zh) * 2017-03-22 2024-04-16 豪夫迈·罗氏有限公司 用于治疗眼部病症的优化的抗体组合物
CN111417651B (zh) * 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体

Also Published As

Publication number Publication date
CA3149350A1 (en) 2021-03-04
JP2022545682A (ja) 2022-10-28
IL290253A (en) 2022-04-01
WO2021041250A1 (en) 2021-03-04
EP4017533A4 (en) 2024-03-27
AU2020337333A1 (en) 2022-03-03
EP4017533A1 (en) 2022-06-29
US20220306760A1 (en) 2022-09-29
CN114269380A (zh) 2022-04-01
BR112022003282A2 (pt) 2022-05-24
KR20220050166A (ko) 2022-04-22

Similar Documents

Publication Publication Date Title
MX2022002239A (es) Glicovariantes de igm.
MX2021007576A (es) Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8).
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
MX2019008146A (es) Virus alterado.
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EP4257611A3 (en) Anti-muc1 antibody
MX2020008030A (es) Anticuerpos de glipicano 3 y conjugados de los mismos.
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
DOP2019000064A (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2018013531A8 (en) AUTO-ANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER
MX2022007676A (es) Anticuerpos caninizados biespecificos para tratar dermatitis atopica.
PE20230381A1 (es) Proteina de union a rgma
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
AU2018278730A1 (en) A novel anti-c-Met antibody and use thereof
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2021000797A (es) Anticuerpos agonistas de cd226.
MX2020010092A (es) Variantes de anticuerpo c-terminales.
MX2021000786A (es) Receptor para supresor de ig del dominio v de activación de células t (vista).